Matches in Wikidata for { <http://www.wikidata.org/entity/Q64123075> ?p ?o ?g. }
- Q64123075 description "article scientifique publié en 2018" @default.
- Q64123075 description "im November 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q64123075 description "scholarly article by Josef S Smolen et al published November 2018 in Annals of the Rheumatic Diseases" @default.
- Q64123075 description "wetenschappelijk artikel" @default.
- Q64123075 description "наукова стаття, опублікована в листопаді 2018" @default.
- Q64123075 name "Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate" @default.
- Q64123075 name "Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate" @default.
- Q64123075 type Item @default.
- Q64123075 label "Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate" @default.
- Q64123075 label "Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate" @default.
- Q64123075 prefLabel "Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate" @default.
- Q64123075 prefLabel "Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate" @default.
- Q64123075 P1433 Q64123075-8C34EE80-D2E6-4C10-9ABA-818A4E47461C @default.
- Q64123075 P1476 Q64123075-71CAB05A-892C-4634-8F19-0B1387526E0E @default.
- Q64123075 P2093 Q64123075-25A21E59-1C49-4088-9B52-0F74EED0FDE4 @default.
- Q64123075 P2093 Q64123075-48EB2AA1-4C5E-45F2-9EB4-00BBDC092FEA @default.
- Q64123075 P2093 Q64123075-63B46FD7-4A62-4F4D-A2C4-5B44EF875FD2 @default.
- Q64123075 P2093 Q64123075-71E6FA24-F218-455F-8697-BE3051363F4F @default.
- Q64123075 P2860 Q64123075-017E32E8-510B-4F48-8653-2D1229313AE8 @default.
- Q64123075 P2860 Q64123075-12246D35-83FE-41F2-8598-6651EEB65D6F @default.
- Q64123075 P2860 Q64123075-188B0B0F-0B44-40D6-944D-06F4D8EE75C7 @default.
- Q64123075 P2860 Q64123075-26395F62-49FE-47D6-BF63-00A38D53DC3B @default.
- Q64123075 P2860 Q64123075-28AFCD6E-76B4-4D66-9013-52A287F3189F @default.
- Q64123075 P2860 Q64123075-30D82FD7-043D-421B-B5EF-3B181B9FEED5 @default.
- Q64123075 P2860 Q64123075-3129F389-842F-4823-A2DB-12AD44A8C5CB @default.
- Q64123075 P2860 Q64123075-45F0C5B2-66F5-4460-9D3D-F0C781CAA349 @default.
- Q64123075 P2860 Q64123075-673A23F2-B94A-474E-9FFB-98029E8F8619 @default.
- Q64123075 P2860 Q64123075-7FC42C90-E998-471D-9E63-D3615A3562C4 @default.
- Q64123075 P2860 Q64123075-856DA65B-90FE-4373-8DCC-5411A86CE978 @default.
- Q64123075 P2860 Q64123075-8A5CB286-34D8-44F5-8B35-439A554368E4 @default.
- Q64123075 P2860 Q64123075-8F0C89AF-47F9-4ADC-AE18-F10504AFA75E @default.
- Q64123075 P2860 Q64123075-95FD0EE4-DF44-47E0-A0E8-65D15258FE3C @default.
- Q64123075 P2860 Q64123075-9CEC0840-0E35-4E31-9DEF-1BA694431D50 @default.
- Q64123075 P2860 Q64123075-A02C7D04-5670-42B9-B9A9-C2EF92A47853 @default.
- Q64123075 P2860 Q64123075-AEF7A4E7-D81D-41AC-915D-D29002FAB13D @default.
- Q64123075 P2860 Q64123075-B3283C4A-4955-41CB-9B88-DD85BEE3615E @default.
- Q64123075 P2860 Q64123075-B8013AE4-0F5A-4216-A7FA-DF9B9507EB7C @default.
- Q64123075 P2860 Q64123075-BB4912AE-F91E-41BC-8387-509A604BB03C @default.
- Q64123075 P2860 Q64123075-BB78D16C-6315-42E3-96F5-A4319C9FAC07 @default.
- Q64123075 P2860 Q64123075-C40AF83F-57BA-4D7D-8397-46AE84F51A9E @default.
- Q64123075 P2860 Q64123075-C42FA52F-4480-4F6F-A33C-4AB9A387D6EC @default.
- Q64123075 P2860 Q64123075-C8A6BA97-3AC1-4F1A-B9BD-30C8588FB993 @default.
- Q64123075 P2860 Q64123075-CB77A6C5-4635-40D4-9F0D-FC0A765CCF57 @default.
- Q64123075 P2860 Q64123075-D8F5112C-C8AF-4538-9D95-AA17E3763AA7 @default.
- Q64123075 P2860 Q64123075-E4915664-B7ED-4496-AA7E-CC6C8666099D @default.
- Q64123075 P2860 Q64123075-EF51E8D1-0E31-4CC4-8C1F-9948E546C9DB @default.
- Q64123075 P2860 Q64123075-F0B94618-3170-464E-B85F-8A43A53B7AE1 @default.
- Q64123075 P2860 Q64123075-F11C5388-1C2A-41E3-8EE3-D11FB7ED1FE2 @default.
- Q64123075 P2860 Q64123075-F28A4507-CC55-4C90-AA68-51FB41952A8A @default.
- Q64123075 P304 Q64123075-BD8EF4F3-4FC1-461D-BBC4-01412E459637 @default.
- Q64123075 P31 Q64123075-4F9D24E5-58CD-4E6D-9E20-7FD49FC38672 @default.
- Q64123075 P356 Q64123075-1353A0A1-32D5-4A51-A9AF-FE6DEFFF6E4C @default.
- Q64123075 P407 Q64123075-879597CD-EBAB-477C-99D4-8F47BD86FEF6 @default.
- Q64123075 P433 Q64123075-FCA608D0-F6FF-4DE0-8AD5-B39A9B182901 @default.
- Q64123075 P478 Q64123075-66313104-4C41-4670-A155-9B44FB4BAF1F @default.
- Q64123075 P50 Q64123075-06B04BC4-C7A6-44D1-B6D2-3C8DFC145F8F @default.
- Q64123075 P50 Q64123075-7715E18E-CB48-485B-AD10-ED411D325C41 @default.
- Q64123075 P577 Q64123075-04C14950-9191-42CA-B67F-E5F08AC1057E @default.
- Q64123075 P698 Q64123075-75A751BD-FCBD-471E-809B-9E1767E74E0A @default.
- Q64123075 P921 Q64123075-0E54DD1C-7922-47CA-8364-02404A5EF188 @default.
- Q64123075 P921 Q64123075-1FF04A20-2061-494E-9E11-753B5F6C9CFA @default.
- Q64123075 P921 Q64123075-D3E272FD-6A0D-4446-9211-0ADB3FE8490F @default.
- Q64123075 P932 Q64123075-14F0BFB3-AD1F-4306-974C-7B04DAB5CE09 @default.
- Q64123075 P356 ANNRHEUMDIS-2018-213502 @default.
- Q64123075 P698 30076156 @default.
- Q64123075 P1433 Q4767876 @default.
- Q64123075 P1476 "Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate" @default.
- Q64123075 P2093 "Jessica L Suboticki" @default.
- Q64123075 P2093 "Ronald F van Vollenhoven" @default.
- Q64123075 P2093 "Stefan Florentinus" @default.
- Q64123075 P2093 "Su Chen" @default.
- Q64123075 P2860 Q33570140 @default.
- Q64123075 P2860 Q33675468 @default.
- Q64123075 P2860 Q34022672 @default.
- Q64123075 P2860 Q34500921 @default.
- Q64123075 P2860 Q34559803 @default.
- Q64123075 P2860 Q35552900 @default.
- Q64123075 P2860 Q35899269 @default.
- Q64123075 P2860 Q36013828 @default.
- Q64123075 P2860 Q36550842 @default.
- Q64123075 P2860 Q36732733 @default.
- Q64123075 P2860 Q36907694 @default.
- Q64123075 P2860 Q37546519 @default.
- Q64123075 P2860 Q38204350 @default.
- Q64123075 P2860 Q38441144 @default.
- Q64123075 P2860 Q39427442 @default.
- Q64123075 P2860 Q40305889 @default.
- Q64123075 P2860 Q40484774 @default.
- Q64123075 P2860 Q43055381 @default.
- Q64123075 P2860 Q46048883 @default.
- Q64123075 P2860 Q50779374 @default.
- Q64123075 P2860 Q51333035 @default.
- Q64123075 P2860 Q51528833 @default.
- Q64123075 P2860 Q55467763 @default.
- Q64123075 P2860 Q57788757 @default.
- Q64123075 P2860 Q70237453 @default.
- Q64123075 P2860 Q70672405 @default.
- Q64123075 P2860 Q71628428 @default.
- Q64123075 P2860 Q81377140 @default.
- Q64123075 P2860 Q82132610 @default.